文献速递妇科

影像引导自适应近距离放疗治疗侵犯膀胱和/或直肠的晚期宫颈癌:临床结局与预后因素

Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors.
PubMed 文献 · Gynecol Oncol · 2022-11-09

回顾性分析2006至2020年Gustave Roussy研究所81例侵犯膀胱和/或直肠的局部晚期宫颈癌患者,接受影像引导自适应近距离放疗。中位随访27.62±25.10个月,34/81例(42%)复发,转移最常见(n=25)。多因素分析显示D90 CTVHR≥75.1 GyEQD2与总生存显著相关(HR=0.23,95%CI 0.07-0.78,P=0.018),膀胱阴道瘘是最常见的局部复发模式(HR=4.6,95%CI 1.5-14,P=0.01)。

要点

  • 侵犯膀胱和/或直肠的局部晚期宫颈癌患者接受影像引导自适应近距离放疗后,34/81例(42%)出现复发。
  • 多因素分析中D90 CTVHR≥75.1 GyEQD2与总生存显著相关(HR=0.23,95%CI 0.07-0.78,P=0.018)。
  • 膀胱阴道瘘是最常见的局部复发模式(HR=4.6,95%CI 1.5-14,P=0.01)。

核心结论

  • 近距离放疗技术的进步改善了局部控制率和生存率,同时降低了毒性。
  • 通过剂量递增和联合腔内/组织间近距离放疗技术增强局部控制,是提高患者治愈概率的主要因素,同时需联合全身强化治疗以更好地控制远处事件。

研究设计与样本

  • 回顾性分析2006年至2020年在Gustave Roussy研究所接受治疗的局部晚期宫颈癌侵犯膀胱和/或直肠患者的医疗记录。
  • 共纳入81例患者,所有患者接受盆腔±腹主动脉旁放疗,45 Gy分25次±大体淋巴结推量。
  • 93.8%的病例接受了同步铂类化疗。
  • 采用Cox回归模型研究临床和剂量学因素与生存终点及瘘管形成的潜在关联。

主要发现

  • 中位D90 CTVHR剂量为75.5 GyEQD2(标准差:10.39 GyEQD2),中位CTVHR体积为47.6 cm3(标准差:27.9 cm3)。
  • 中位膀胱D2cm3剂量为75.04 GyEQD2(标准差:8.72 GyEQD2),中位直肠D2cm3剂量为64.07 GyEQD2(标准差:6.68 GyEQD2)。
  • 中位随访27.62±25.10个月后,34/81例患者(42%)发现复发,转移性失败是最常见的复发模式(n=25)。
  • 单因素分析中,使用联合组织间/腔内技术和D90 CTVHR≥75.1 GyEQD2是总生存的预后因素(分别为HR=0.24,95%CI:0.057-1,P=0.023;HR=0.2,95%CI:0.059-0.68,P=0.0025)。
  • 多因素分析中,D90 CTVHR≥75.1 GyEQD2对总生存有显著意义(HR=0.23;95%CI:0.07,0.78,P=0.018)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Refinements of brachytherapy techniques have led to better local control of locally advanced cervical cancer (LACC), especially with the development of image-guided adaptive brachytherapy (IGABT). Data on the efficacy of brachytherapy in cervical cancer spreading to adjacent organs are scarce. We report the experience of our institution in the treatment of these advanced tumors with IGABT. MATERIALS AND METHODS: Medical records of patients treated for a LACC spreading to the bladder and/or rectum between 2006 and 2020 at Gustave Roussy Institute were analyzed. Dosimetric parameters were collected and converted into 2 Gy per fraction equivalent doses, including the minimal dose received by 90% of the high-risk target volume (D90 CTVHR) and intermediate-risk target volume (D90 CTVIR), as well as the dose received by the most exposed 2 cm3 of the organs at risk. A Cox regression model was used to study the potential associations between clinical and dosimetric factors with survival endpoints and fistula formation. RESULTS AND STATISTICAL ANALYSIS: A total of 81 patients were identified. All patients received pelvic+/- para-aortic radiotherapy, 45 Gy in 25 fractions +/- boost to gross lymph nodes. Concomitant platinum-based chemotherapy was administered in 93.8% of cases. The median D90 CTVHR dose was 75.5 GyEQD2 (SD: 10.39 GyEQD2) and median CTVHR volume was 47.6 cm3 (SD: 27.9 cm3). Median bladder and rectal D2cm3 dose were 75.04 GyEQD2 (SD: 8.72 GyEQD2) and 64.07 GyEQD2 (SD: 6.68 GyEQD2). After a median follow-up of 27.62 ± 25.10 months, recurrence was found in 34/81 patients (42%). Metastatic failure was the most common pattern of relapse (n = 25). Use of a combined interstitial/intracavitary technique and D90 CTVHR ≥ 75.1 GyEQD2 were prognostic factors for OS in univariate analysis (HR = 0.24, 95%IC: 0.057-1, p = 0.023; HR = 0.2, 95%IC: 0.059-0.68, p = 0.0025, respectively). In multivariate analysis, a D90 CTVHR ≥ 75.1 GyEQD2 was significant for OS (HR = 0.23; 95%IC: 0.07, 0.78, p = 0.018). The occurrence of vesicovaginal fistula (VVF) was the most frequent pattern of local recurrence (HR = 4.6, 95%CI: 1.5-14, p = 0.01). CONCLUSION: Advances in brachytherapy modalities improved local control and survival while reducing toxicities. Enhancing local control through dose escalation and combined intracavitary/interstitial brachytherapy techniques is a major factor in patients cure probability, together with systemic intensification to better control distant events.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ka K, Laville A, Rassy E, et al. Image-guided adaptive brachytherapy for advanced cervical cancer spreading to the bladder and/or rectum: Clinical outcome and prognostic factors. Gynecol Oncol. 2022. PMID: 36370612. doi:10.1016/j.ygyno.2022.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。